Research programme: anti-CD44 antibodies - Roche

Drug Profile

Research programme: anti-CD44 antibodies - Roche

Alternative Names: AR001; AR11BD-2E11-2; AR53A10.11; AR58A314.1; AR6BD-25; ARH460-16-2; ARH460-23

Latest Information Update: 05 Nov 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARIUS Research
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Sep 2008 ARIUS Research has been acquired by Roche
  • 03 Jun 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 28 Jan 2008 ARIUS completes pre-IND meeting with the US FDA for ARH460-16-2
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top